company background image
MEDC

MedinCell ENXTPA:MEDCL Stock Report

Last Price

€5.55

Market Cap

€139.4m

7D

-3.6%

1Y

-49.3%

Updated

26 May, 2022

Data

Company Financials +
MEDCL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health1/6
Dividends0/6

MEDCL Stock Overview

MedinCell S.A. develops various therapeutic solutions.

MedinCell Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MedinCell
Historical stock prices
Current Share Price€5.55
52 Week High€11.60
52 Week Low€5.18
Beta1.16
1 Month Change-4.80%
3 Month Change-24.08%
1 Year Change-49.27%
3 Year Change-20.71%
5 Year Changen/a
Change since IPO-24.49%

Recent News & Updates

Shareholder Returns

MEDCLFR PharmaceuticalsFR Market
7D-3.6%2.5%-1.1%
1Y-49.3%16.9%-5.9%

Return vs Industry: MEDCL underperformed the French Pharmaceuticals industry which returned 16.9% over the past year.

Return vs Market: MEDCL underperformed the French Market which returned -5.9% over the past year.

Price Volatility

Is MEDCL's price volatile compared to industry and market?
MEDCL volatility
MEDCL Average Weekly Movement12.2%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement5.9%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market3.4%

Stable Share Price: MEDCL is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MEDCL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a150Christophe Douathttps://www.medincell.com

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company’s products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia.

MedinCell Fundamentals Summary

How do MedinCell's earnings and revenue compare to its market cap?
MEDCL fundamental statistics
Market Cap€139.42m
Earnings (TTM)-€20.02m
Revenue (TTM)€12.71m

11.0x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MEDCL income statement (TTM)
Revenue€12.71m
Cost of Revenue€0
Gross Profit€12.71m
Other Expenses€32.73m
Earnings-€20.02m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Jun 14, 2022

Earnings per share (EPS)-0.80
Gross Margin100.00%
Net Profit Margin-157.56%
Debt/Equity Ratio-2,549.6%

How did MEDCL perform over the long term?

See historical performance and comparison

Valuation

Is MedinCell undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MEDCL (€5.55) is trading below our estimate of fair value (€132.73)

Significantly Below Fair Value: MEDCL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MEDCL is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Pharmaceuticals industry average.

PE vs Market: MEDCL is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MEDCL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MEDCL has negative assets, so we can't compare its Price-To-Book Ratio to the FR Pharmaceuticals industry average.


Future Growth

How is MedinCell forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


108.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDCL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: MEDCL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MEDCL's is expected to become profitable in the next 3 years.

Revenue vs Market: MEDCL's revenue (85.9% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: MEDCL's revenue (85.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MEDCL's Return on Equity is forecast to be very high in 3 years time (49.7%).


Past Performance

How has MedinCell performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-19.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MEDCL is currently unprofitable.

Growing Profit Margin: MEDCL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MEDCL is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.

Accelerating Growth: Unable to compare MEDCL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MEDCL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).


Return on Equity

High ROE: MEDCL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is MedinCell's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MEDCL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MEDCL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MEDCL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MEDCL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MEDCL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MEDCL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is MedinCell current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


9.01%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MEDCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MEDCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MEDCL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEDCL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MEDCL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Christophe Douat (55 yo)

7.83yrs

Tenure

€336,333

Compensation

Mr. Christophe Douat serves as Chairman of the Management Board and Chief Executive officer at MedinCell S.A and served as General Manager. Mr. Douat serves as an Investment Director of Matignon Investisse...


CEO Compensation Analysis

Compensation vs Market: Christophe's total compensation ($USD360.79K) is about average for companies of similar size in the French market ($USD287.59K).

Compensation vs Earnings: Christophe's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MEDCL's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: MEDCL's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MedinCell S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: MedinCell S.A.
  • Ticker: MEDCL
  • Exchange: ENXTPA
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €139.419m
  • Shares outstanding: 25.12m
  • Website: https://www.medincell.com

Number of Employees


Location

  • MedinCell S.A.
  • 3 rue des Frères Lumière
  • Jacou
  • Languedoc-Roussillon
  • 34830
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/26 00:00
End of Day Share Price2022/05/26 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.